Indeed, variants in TM6SF2 as well as microsomal triglyceride transfer protein (MTTP) and APOB have already been identified as MASLD risk factors having direct influence over VLDL secretion (7–10), and the current experiments add Hdlbp to this list. The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.